Extracorporeal plasma treatment in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: a review.
This review summarizes the state of the art of apheresis in hemolytic uremic syndrome (HUS) and in thrombotic thrombocytopenic purpura (TTP). Both entities are characterized by thrombotic microangiopathy, hemolytic anemia, and thrombocytopenia. While HUS often presents with renal insufficiency, cerebral involvement is more common in TTP. Recently, in TTP, a primary or secondary lack of activity of a von Willebrand factor (vWF) degrading enzyme was made responsible for the presence of unusually large vWF multimers causing platelet aggregation and thrombus formation in the microvasculature. In contrast, in familial HUS, a factor H deficiency with uninhibited complement activation seems to play a role. Therapeutic plasma exchange (TPE) using fresh frozen plasma or cryosupernatant as the substitution fluid is indicated in acute TTP and atypical HUS without antecedent diarrhea. As a rule, it will show good effectiveness, especially in the former entity. HUS in pregnancy should be treated by instant delivery whereas postpartum HUS may resolve using protracted courses of TPE. In contrast, in thrombotic microangiopathy after bone marrow transplantation as well as in HUS due to cancer, mitomycin C, or after renal transplantation, TPE is of questionable value and indicated only as a last resort treatment.
Bosch
T
T
Department of Internal Medicine I, Klinikum Grosshadern, University of Munich, Germany. bosch@med1.med.uni-muenchen.de
Wendler
T
T
D005112:Extracorporeal Circulation; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008297:Male; D010956:Plasmapheresis; D011247:Pregnancy; D011697:Purpura, Thrombotic Thrombocytopenic / Q000503:physiopathology / Q000628:therapy*